Table 1.
Baseline Patient Characteristics
| Upfront Zoledronate (N=274) | Delayed Zoledronate (N=277) | Total (N=551) | p value | |
|---|---|---|---|---|
| Age | 0.751 | |||
| N | 274 | 277 | 551 | |
| Mean (SD) | 59.2 (11.20) | 59.6 (10.25) | 59.4 (10.72) | |
| Median | 58.5 | 59.0 | 59.0 | |
| Q1, Q3 | 52.0, 68.0 | 52.0, 67.0 | 52.0, 67.0 | |
| Range | (0.0-82.0) | (0.0-83.0) | (0.0-83.0) | |
| Gender | 0.082 | |||
| female | 271 (98.9%) | 277 (100%) | 548 (99.5%) | |
| male | 3 (1.1%) | 0 (0%) | 3 (0.5%) | |
| Race | 0.502 | |||
| White | 269 (98.2%) | 268 (96.8%) | 537 (97.5%) | |
| Black or African American | 4 (1.5%) | 6 (2.2%) | 10 (1.8%) | |
| Asian | 1 (0.4%) | 0 (0%) | 1 (0.2%) | |
| American Indian or Alaska Native | 0 (0%) | 1 (0.4%) | 1 (0.2%) | |
| Not reported: patient refused or not available | 0 (0%) | 1 (0.4%) | 1 (0.2%) | |
| Unknown: Patient unsure | 0 (0%) | 1 (0.4%) | 1 (0.2%) | |
| Performance Score | 0.872 | |||
| 0 | 261 (95.3%) | 263 (94.9%) | 524 (95.1%) | |
| 1 | 13 (4.7%) | 14 (5.1%) | 27 (4.9%) | |
| Baseline BMD T Score | 0.952 | |||
| > −1 SD | 152 (55.5%) | 153 (55.2%) | 305 (55.4%) | |
| between −1 to −2 SD | 122 (44.5%) | 124 (44.8%) | 246 (44.6%) | |
| Prior Tamoxifen Duration | 0.952 | |||
| ≤ 2 years | 61 (22.3%) | 61 (22%) | 122 (22.1%) | |
| > 2 years | 213 (77.7%) | 216 (78%) | 429 (77.9%) | |
| Time Since Tamoxifen Ended | 0.982 | |||
| < 1 year | 264 (96.4%) | 267 (96.4%) | 531 (96.4%) | |
| ≥ 1 year | 10 (3.6%) | 10 (3.6%) | 20 (3.6%) | |
| Prior Chemotherapy | 0.852 | |||
| Yes | 190 (69.3%) | 190 (68.6%) | 380 (69%) | |
| No | 84 (30.7%) | 87 (31.4%) | 171 (31%) |
1
Kruskal Wallis
2
Chi-Square